Advertisement

Digestive Diseases and Sciences

, Volume 61, Issue 9, pp 2619–2626 | Cite as

Extra-Gastrointestinal Manifestations of Inflammatory Bowel Disease May Be Less Common Than Previously Reported

  • Timothy R. CardEmail author
  • Sinéad M. Langan
  • Thomas P. C. Chu
Original Article

Abstract

Background and Aims

Extra-intestinal manifestations are well recognized in inflammatory bowel disease (IBD). To what extent the commonly recognized extra-intestinal manifestations seen in IBD patients are attributable to IBD is, however, not clear due to the limited number of controlled studies published.

Methods

We have conducted a study of these manifestations using electronic primary care records. We have identified extra-intestinal manifestations in IBD and non-IBD patients and derived odds ratios (ORs) using conditional logistic regression.

Results

A total of 56,097 IBD patients (32.5 % Crohn’s disease, 48.3 % ulcerative colitis (UC) and 19.2 % not classified) were matched to 280,382 non-IBD controls. We found records of pyoderma gangrenosum (OR = 29.24), erythema nodosum (OR = 5.95), primary sclerosing cholangitis (OR = 188.25), uveitis (OR = 2.81), ankylosing spondylitis (OR = 7.07), sacroiliitis (OR = 2.79) and non-rheumatoid inflammatory arthritides (OR = 2.66) to be associated with IBD. One or more of these was recorded in 8.1 % of IBD patients and 2.3 % of controls. Non-specific arthritides were present in many more patients, affecting 30 % of IBD patients and 23.8 % of controls overall. We also found weaker associations with a number of conditions not generally considered to be extra-intestinal manifestations including psoriasis, ischemic heart disease, multiple sclerosis and hay fever.

Conclusion

Although “classical” extra-intestinal manifestations are strongly associated with IBD, most IBD patients remain unaffected. Arthropathies, perceived to be the commonest extra-intestinal manifestation, are not strongly associated with IBD, and the proportion of arthropathies attributable to IBD is likely to be small.

Keywords

Inflammatory bowel diseases Epidemiology Arthritis Iritis Pyoderma 

Abbreviations

IBD

Inflammatory bowel disease

UC

Ulcerative colitis

PSC

Primary sclerosing cholangitis

VTE

Venous thromboembolism

EIMs

Extra-intestinal manifestations

CPRD

Clinical Practice Research Datalink

BMI

Body mass index

OR

Odds ratio

CI

Confidence interval

Notes

Acknowledgments

This work was funded by a grant from Crohn’s and Colitis UK (NACC) (Grant Number M/10/01). This study was conceived and designed collaboratively by all authors. Dr. Card obtained funding. Dr. Chu carried out all analysis. All authors contributed to the interpretation of the results. Drs. Card and Chu jointly wrote the first draft after discussions among all authors, and all authors edited and amended this and all subsequent drafts. All authors approved the final draft. Dr. Langan is funded by an NIHR Clinician Scientist Fellowship (NIHR/CS/010/014). The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the UK Department of Health.

Compliance with ethical standards

Conflict of interest

All authors declare they have no conflict of interest relating to the presented work.

References

  1. 1.
    Bernstein CN, Blanchard JF, Houston DS, et al. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost. 2001;85:430–434.PubMedGoogle Scholar
  2. 2.
    Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet. 2010;375:657–663. doi: 10.1016/S0140-6736(09)61963-2.CrossRefPubMedGoogle Scholar
  3. 3.
    Hammer B, Ashurst P, Naish J. Diseases associated with ulcerative colitis and Crohn’s disease. Gut. 1968;9:17–21. doi: 10.1136/gut.9.1.17.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Acheson ED. An association between ulcerative colitis, regional enteritis, and ankylosing spondylitis. Q J Med. 1960;29:489–499. http://www.ncbi.nlm.nih.gov/pubmed/13681207.
  5. 5.
    Vavricka SR, Brun L, Ballabeni P, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol. 2011;106:110–119. doi: 10.1038/ajg.2010.343.CrossRefPubMedGoogle Scholar
  6. 6.
    Lakatos L, Pandur T, David G, et al. Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study. World J Gastroenterol. 2003;9:2300–2307. http://www.ncbi.nlm.nih.gov/pubmed/14562397. Accessed Jun 12, 2013.
  7. 7.
    Williams H, Walker D, Orchard TR. Extraintestinal manifestations of inflammatory bowel disease. Curr Gastroenterol Rep. 2008;10:597–605. http://www.ncbi.nlm.nih.gov/pubmed/19006617. Accessed Oct 9, 2013.
  8. 8.
    Bernstein CN, Blanchard JF, Rawsthorne P, et al. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2001;96:1116–1122. doi: 10.1111/j.1572-0241.2001.03756.x.CrossRefPubMedGoogle Scholar
  9. 9.
    Alonso Farto JC, Arias IA, Lopez Longo FJ, et al. Clinical significance of abdominal scintigraphy using 99mTc-HMPAO-labelled leucocytes in patients with seronegative spondyloarthropathies. Eur J Nucl Med. 2000;27:1768–1773. doi: 10.1007/s002590000393.CrossRefGoogle Scholar
  10. 10.
    Ciccacci C, Biancone L, Di Fusco D, et al. TRAF3IP2 gene is associated with cutaneous extraintestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2013;7:44–52. doi: 10.1016/j.crohns.2012.02.020.CrossRefPubMedGoogle Scholar
  11. 11.
    Langan SM, Groves RW, Card TR, et al. Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study. J Invest Dermatol. 2012;132:2166–2170. doi: 10.1038/jid.2012.130.CrossRefPubMedGoogle Scholar
  12. 12.
    Lewis JD, Brensinger C, Bilker WB, et al. Validity and completeness of the General Practice Research Database for studies of inflammatory bowel disease. Pharmacoepidemiol Drug Saf. 2002;11:211–218. doi: 10.1002/pds.698.CrossRefPubMedGoogle Scholar
  13. 13.
    Herrett E, Thomas SL, Schoonen WM, et al. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol. 2010;69:4–14. doi: 10.1111/j.1365-2125.2009.03537.x.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Jick H, Terris BZ, Derby LE, et al. Further validation of information recorded on a general practitioner based computerized data resource in the united kingdom. Pharmacoepidemiol Drug Saf. 1992;1:347–349. doi: 10.1002/pds.2630010607.CrossRefGoogle Scholar
  15. 15.
    Cullinan E. Ulcerative colitis: clinical aspects. Br Med J. 1938;2:1351–1356. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2211132/. Accessed Dec 2, 2013.
  16. 16.
    Steinberg VL, Storey G. Ankylosing spondylitis and chronic inflammatory lesions of the intestines. Br Med J. 1957;2:1157–1159. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1963013&tool=pmcentrez&rendertype=abstract. Accessed Dec 2, 2013.
  17. 17.
    Billson FA, De Dombal FT, Watkinson G, et al. Ocular complications of ulcerative colitis. Gut. 1967;8:102–106. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1552509&tool=pmcentrez&rendertype=abstract. Accessed Oct 14, 2013.
  18. 18.
    Christodoulou DK, Katsanos KH, Kitsanou M, et al. Frequency of extraintestinal manifestations in patients with inflammatory bowel disease in Northwest Greece and review of the literature. Dig Liver Dis. 2002;34:781–786.CrossRefPubMedGoogle Scholar
  19. 19.
    Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis. III. Complications. Gut. 1964;5:1–22. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1552214&tool=pmcentrez&rendertype=abstract. Accessed May 30 2012.
  20. 20.
    Bernstein CN, Wajda A, Blanchard JF. The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study. Clin Gastroenterol Hepatol. 2008;6:41–45. doi: 10.1016/j.cgh.2007.09.016.CrossRefPubMedGoogle Scholar
  21. 21.
    Gupta G, Gelfand JM, Lewis JD. Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology. 2005;129:819–826.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Timothy R. Card
    • 1
    • 2
    Email author
  • Sinéad M. Langan
    • 3
  • Thomas P. C. Chu
    • 1
  1. 1.Division of Epidemiology and Public HealthUniversity of NottinghamNottinghamUK
  2. 2.Nottingham Digestive Diseases Centre Biomedical Research UnitUniversity of NottinghamNottinghamUK
  3. 3.Faculty of Epidemiology and Population HealthLondon School of Hygiene and Tropical MedicineLondonUK

Personalised recommendations